Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Open access
Pillai, Vinodh, Muralidharan, Kavitha, Meng, Wenzhao, Bagashev, Asen, Oldridge, Derek A., Rosenthal, Jaclyn, Van Arnam, John, Melenhorst, Jos J., Mohan, Diwakar, DiNofia, Amanda M., Luo, Minjie, Cherian, Sindhu, Fromm, Jonathan R., Wertheim, Gerald, Thomas-Tikhonenko, Andrei, Paessler, Michele, June, Carl H., Luning Prak, Eline T., Bhoj, Vijay G., Grupp, Stephan A., Maude, Shannon L., Rheingold, Susan R. · 2019 · Blood Advances

Abstract

Key Points: Preinfusion dim CD19 expression and rare CD19– events in B-ALL do not affect relapses or responses to CD19-directed CAR T-cells. Prior blinatumomab treatment increases the rate of failure to achieve MRD– remission and CD19– MRD and relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000692

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 206

Metadata

Authors
Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Rosenthal, J., Van Arnam, J., Melenhorst, J. J., Mohan, D., DiNofia, A. M., Luo, M., Cherian, S., Fromm, J. R., Wertheim, G., Thomas-Tikhonenko, A., Paessler, M., June, C. H., Luning Prak, E. T., Bhoj, V. G., Grupp, S. A., Maude, S. L., & Rheingold, S. R.
Venue
Blood Advances
Published
2019-11-18
Volume
3
Issue
22
Pages
3539-3549
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2985081230
Cited by
206
References
5
FWCI
9.79
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000692
The paper
Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Rosenthal, J., Van Arnam, J., Melenhorst, J. J., Mohan, D., DiNofia, A. M., Luo, M., Cherian, S., Fromm, J. R., Wertheim, G., Thomas-Tikhonenko, A., Paessler, M., June, C. H., Luning Prak, E. T., Bhoj, V. G., . . . Rheingold, S. R. (2019). CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000692

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.